The starting material for virtually all pharmaceuticals and biologics is a synthetic or chemical. Human plasma-derived therapies are one of the few exceptions. A number of fragile proteins can be ...

Most research labs can make cells that produce antibodies. The trick is making those antibodies in sufficient quantity and quality to use throughout clinical trials and for manufacturing scale-up.